ERNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ernexa Therapeutics Inc (ERNA) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is extremely weak, with revenue, net income, EPS, and gross margin all showing significant declines. Technical indicators suggest bearish trends with no clear buy signals, and there are no positive news or catalysts to support a potential recovery. Additionally, there is no recent trading activity from insiders, hedge funds, or Congress to indicate confidence in the stock. Given the lack of positive momentum and poor financials, it is better to avoid this stock.
The stock is showing bearish trends with moving averages in a downward pattern (SMA_200 > SMA_20 > SMA_5). RSI is neutral at 39.355, and MACD is positive but contracting, indicating no strong momentum. Support levels are at 0.189 and 0.18, while resistance is at 0.221 and 0.23, but the stock is not showing signs of breaking resistance.
NULL identified. No recent news or events to act as a positive catalyst.
Significant financial underperformance in the latest quarter, with revenue, net income, EPS, and gross margin all showing steep declines. No insider or hedge fund activity to indicate confidence in the stock.
In Q4 2025, the company reported a 100% YoY revenue decline to $0, a 73.82% YoY decline in net income to -$1,510,000, a 92.04% YoY decline in EPS to -0.18, and a 100% decline in gross margin to 0%.
No analyst rating or price target changes available.
